Tonix Pharmaceuticals stock halted ahead of FDA approval news
Mirum Pharmaceuticals (NASDAQ:MIRM), a $3.25 billion market cap biopharmaceutical company whose stock has surged over 21% in the past week, reported that Chief Financial Officer Eric Bjerkholt sold 8,000 shares of common stock on August 11, 2025, for approximately $524,000. The shares were sold at a weighted average price of $65.50, with prices ranging from $65.31 to $66.00.
On August 12, Bjerkholt also exercised options to acquire 2,954 shares of Mirum Pharmaceuticals stock at a price of $26.49 per share, for a total value of $78,251.
Following these transactions, Bjerkholt directly owns 31,190 shares of Mirum Pharmaceuticals.
In other recent news, Mirum Pharmaceuticals reported strong financial results for the second quarter of 2025. The company achieved total revenues of $127.8 million, marking a 64% increase from the same period in 2024. This revenue figure surpassed expectations, with analysts having projected $107.36 million. Additionally, Mirum posted an earnings per share of -$0.12, which was significantly better than the anticipated -$0.33. Following these results, JMP Securities raised its price target for Mirum Pharmaceuticals to $81, maintaining a Market Outperform rating, while H.C. Wainwright increased its price target to $80, continuing with a Buy rating. Stifel also resumed coverage of Mirum with a Buy rating and set a price target of $89. The firm noted Mirum’s positive cash flow and growth potential, especially with upcoming catalysts in its pipeline. These developments highlight the company’s strong position and potential for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.